Over 100 years serving the Lord home and around the world
First Baptist Church
We are a church who's members come from many nations of origin to worship together!

Among the worlds leading study and advisory firms for pharmaceutical and healthcare issues.

Study of 51 endocrinologists, 51 gynecologists, 52 PCPs and 20 MCO pharmacy directors.. Amgen/GSK’s Prolia will be preferred seeing that second – or third-line therapy for osteoporosis Decision Resources, among the world’s leading study and advisory firms for pharmaceutical and healthcare issues, finds that the majority of surveyed clinicians say they’ll use Amgen/GlaxoSmithKline’s Prolia seeing that either a second – or third-collection therapy for osteoporosis if the drug receives regulatory acceptance for the indication. Prolia, which is likely to receive acceptance from the Medication and Food Administration in early 2010, will be prescribed in afterwards lines of therapy as most surveyed clinicians indicate that they will likely continue using bisphosphonates as first-line treatments.Prolia reduces the chance of fracture through a easy injection given every half a year. Amgen can be proud to make this new treatment open to doctors and their patients. Related StoriesCornell biomedical engineers develop 'super organic killer cells' to destroy malignancy cells in lymph nodesViralytics enters into medical trial collaboration agreement with MSDMD Anderson research reveals why chemotherapy drugs not effective for many pancreatic cancer patientsThe marketing authorization for Prolia comprises data from six Stage 3 trials, including two pivotal Phase 3 research with fracture endpoints in the prostate and osteoporosis cancers settings, which demonstrated that Prolia administered as a 60mg subcutaneous injection every half a year decreases the incidence of fractures.